New Study Reveals the Effects of Repeated mRNA Vaccinations on the Immune System

A study published in the journal *Scientific Reports* in August 2026 raises new questions regarding the long-term immunological effects of repeated mRNA vaccinations against COVID-19. Researchers observed a persistent shift in the antibody response toward the IgG4 subclass in both adults and children. Notably, in one group of adults studied, higher levels of IgG4 were associated with an increased risk of subsequent breakthrough SARS-CoV-2 infections.

The study, published on August 12, 2026, examined the immune responses of 104 Swedish healthcare workers who had received five to six doses of mRNA vaccines. Additionally, the researchers analyzed blood samples from 18 children in Singapore following two to three vaccinations.

The investigation focused on how repeated vaccination affects the composition and properties of antibodies directed against the spike protein over the long term.

The results indicate that repeated administration of mRNA vaccines not only influences the quantity of antibodies but also alters their composition.

A Noticeable Shift Toward IgG4

Under normal circumstances, the early antibody response against the spike protein is primarily driven by IgG1. In addition to their ability to recognize the virus, these antibodies can activate various immune response mechanisms.

In contrast, IgG4 possesses different properties. It activates certain pro-inflammatory defense mechanisms much less strongly and is often associated with an immunological adaptation to repeated or prolonged antigen exposure.

Scientists observed precisely this shift following repeated mRNA vaccinations.

Among participants who had not contracted a SARS-CoV-2 infection prior to their first vaccination, the average proportion of spike-specific IgG4 antibodies reached 26.8 percent following the sixth vaccination. Some individual participants showed levels as high as 75 percent.

The duration of this effect is particularly significant: the altered antibody composition persisted throughout the entire study period, even after repeated vaccinations. The researchers monitored a cohort of adults for a total of five years.

This does not mean that all of the immune system’s antibodies have been replaced by IgG4. The observed change pertains specifically to the immune response against the spike protein. Nevertheless, it represents a significant and persistent immunological adaptation.

Higher IgG4 levels are associated with breakthrough infections

Another finding concerns the question of whether this shift in antibodies might have practical implications for infection control.

To investigate this, the researchers examined a subgroup of 41 adults who had received three vaccine doses and had not yet been infected with the SARS-CoV-2 virus at the time of the study.

In these individuals, a statistical correlation was found between IgG4 levels and the risk of a subsequent breakthrough infection.

The researchers determined a hazard ratio of 1.83 for every standard deviation increase in IgG4 levels. Simply put, higher IgG4 levels in this group were associated with an increased risk of subsequent infection.

However, the study does not yet prove that IgG4 itself causes infections. Establishing this would require larger-scale studies and a direct examination of the underlying immune mechanisms.

Nevertheless, it is noteworthy that the researchers not only documented a change in antibody composition but also identified a link to a specific health outcome.

The breakthrough infections observed in this group were either asymptomatic or mild.

Prior infection had a significant impact

The influence of an individual’s immune history is particularly interesting.

The researchers distinguished between people who were vaccinated first and those who had already contracted a SARS-CoV-2 infection prior to their first vaccination.

In the first group, the shift toward IgG4 was significantly more pronounced.

In contrast, individuals with a prior infection exhibited lower average levels of IgG4. In this group, no comparable, statistically significant increase was observed following repeated vaccination.

The researchers therefore suspect that the immune system’s initial encounter with the virus—or its spike protein—may have a long-term effect on how it responds to subsequent vaccinations.

This brings to the fore a question that was often only touched upon during vaccination campaigns: What is the significance of the sequence of natural infection versus vaccination for the long-term quality of the immune response?

The study demonstrates that this sequence is immunologically relevant. However, it does not definitively answer which vaccination strategy is most advantageous for specific population groups in the long term.

Also observed in children

The researchers observed similar changes in a smaller group of children from Singapore.

The eighteen children monitored were between five and twelve years old and had received two to three doses of an mRNA vaccine. They also exhibited changes in IgG subclasses and certain antibody characteristics, similar to those identified in the adult participants. However, due to the small number of participants, the researchers were unable to investigate whether there is also a correlation between elevated IgG4 levels and subsequent breakthrough infections in children.

The observations indicate, however, that these shifts in antibodies do not occur exclusively in adults.

What are the consequences of an altered immune response?

A key question concerns the function of these IgG4 antibodies.

While IgG4 can still recognize pathogens or their components, certain other defensive functions—such as activating the complement system or interacting with various immune cells—are less pronounced compared to other IgG subclasses.

Therefore, a stronger IgG4 response could theoretically influence how the body reacts to subsequent exposure to SARS-CoV-2.

Researchers are also discussing changes in what is known as Fc glycosylation—chemical structures on antibodies that influence how they interact with immune cells.

In this area, too, they observed long-term differences between individuals with and without a prior infection.

It remains unclear whether these changes actually lead to a diminished immune response or if they are compensated for by other components of the immune system. While the study offers some indications in this regard, it does not provide conclusive evidence regarding their function.

Five years of observation—many questions remain

The study is particularly notable for its long observation period and repeated blood sampling. In total, the researchers analyzed 831 samples from adult participants.

This allowed them to track how the antibody response evolved over the course of multiple vaccinations and infection events.

At the same time, the study has its limitations. The analysis of the risk of breakthrough infection included only 41 adults, all of whom were women. The results may also have been influenced by differences in viral variants, exposure to infection, and the timing of vaccination.

The authors therefore explicitly state that the clinical significance of this IgG4 shift has not yet been fully elucidated.

They also emphasize that their findings do not negate the proven protection provided by mRNA vaccines against severe cases of COVID-19.

What does this mean for recommendations regarding repeat vaccination?

The study indicates that repeated mRNA vaccination can induce a persistent change in the specific immune response, the long-term consequences of which are not yet fully understood.

Three observations are particularly noteworthy: the IgG4 shift remained detectable for several years; it was especially pronounced in individuals with no prior infection; and, within the studied subgroup, higher IgG4 levels were associated with an increased risk of breakthrough infections.

This raises the question of whether, in the context of repeated booster vaccinations, future considerations should look beyond mere neutralizing antibody levels—taking into account which antibody classes are produced and how effectively these classes actually contribute to defense against the virus.

The results do not demonstrate that mRNA vaccines generally damage the immune system. However, they clearly show that the long-term assessment of repeat vaccinations should not be based solely on antibody levels.

Source: https://www.nature.com/articles/s41598-026-64190-8

Image: Pexels.com